Rates of Active TB After LTBI Treatment
Treatment of latent tuberculosis infection is highly effective, reducing the risk of progression to active TB disease by approximately 60-90%, with protection lasting up to 19 years 1.
Baseline Risk Without Treatment
If left untreated, approximately 5-15% of persons with LTBI will progress to active TB disease during their lifetime, with the majority developing disease within the first 5 years after initial infection 1. The 2020 CDC/NTCA guidelines note that progression from untreated LTBI accounts for approximately 80% of U.S. TB disease cases 2.
Risk Reduction With Treatment
General Population Studies
The evidence demonstrates substantial risk reduction with LTBI treatment:
In close contacts of smear-positive TB cases: A 5-year study showed the risk of developing active TB was 11.5% in untreated subjects versus 1.9% in treated subjects 3. This represents an 81% risk reduction with treatment 4.
In a large contact tracing cohort: Among 953 contacts with LTBI, the 5-year TB risk was 1.0% for those not referred for treatment, 1.2% for those completing treatment, and 11.1% for those who did not complete treatment 5. Not completing LTBI treatment increased TB risk 9-fold (HR 9.4) 5.
Special Populations
Immunosuppressed patients on TNF inhibitors: Even after standard LTBI treatment, the TB incidence was 1,107 per 100,000 patient-years in LTBI-positive patients versus 490 per 100,000 in LTBI-negative patients, though this difference was not statistically significant 6. A more recent 2025 study found 1.3% of patients on TNF-α blockers developed TB despite screening and treatment 7.
Hospitalized patients in China: Among hospitalized LTBI patients, the 1-year TB incidence was 614 per 100,000 and the 5-year cumulative incidence was 1,496 per 100,000 (incidence density 240 per 100,000 person-years) 8.
Critical Timing Considerations
Delayed reactivation can occur even after completing treatment. In one outbreak study, among 105 individuals who received 6 months of isoniazid treatment, 5 (4.8%) developed TB with an average time to reactivation of 53 months after identification of the source case 4. Another Japanese surveillance study found that among those who completed LTBI treatment, 12 cases were diagnosed within 1 year and 22 within 2 years of treatment completion 9.
Risk Factors for TB Development Despite Treatment
The following factors increase risk of progression to active TB even after LTBI treatment:
- Exposure history: Close contact with smear-positive PTB (HR 10.6) 8
- High immunosuppression: Maximum daily glucocorticoid dose ≥50 mg/day (HR 2.9) 8
- Specific immunosuppressants: Leflunomide treatment (HR 8.6) 8
- Anemia (HR 2.6) 8
- High T-SPOT.TB levels: ≥300 SFCs/10⁶ PBMCs (HR 4.2) 8
- Treatment non-completion: The single most important modifiable risk factor 5
Clinical Implications
The most critical determinant of treatment success is completion of the prescribed regimen. The 2020 CDC/NTCA guidelines strongly recommend short-course rifamycin-based regimens (3-4 months) over longer isoniazid monotherapy (6-9 months) specifically because they achieve higher completion rates while maintaining efficacy 2.
Common Pitfall
Do not assume that completing LTBI treatment provides absolute protection. While treatment reduces risk by 60-90%, breakthrough TB can occur, particularly in the first 2-5 years post-treatment and especially in immunocompromised patients. Maintain clinical vigilance for TB symptoms in high-risk patients even after successful LTBI treatment completion.